Vertex to Acquire Crinetics in $10B Deal to Expand Endocrinology Portfolio

Boston, MA, July 12, 2026 (Yahoo Finance) -- Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a transaction valued at approximately $10 billion. The acquisition strengthens Vertex’s endocrinology pipeline by adding Crinetics’ portfolio of therapies for endocrine disorders, including late-stage programs. The deal supports Vertex’s strategy to diversify its portfolio beyond rare diseases and expand its presence in endocrine medicine.

Read full article here.